ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ペルフェナジン

Perphenazine

HCID 4748
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
58-39-9
標準SMILES
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
InChIKey
RGCVKNLCSQQDEP-UHFFFAOYSA-N
分子式
C21H26ClN3OS
平均分子量
404 g/mol
単同位体質量
403.1485113

概要

Perphenazine is a phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist and an antiemetic. It is an organochlorine compound, a member of phenothiazines, a N-alkylpiperazine and a N-(2-hydroxyethyl)piperazine. It derives from a hydride of a 10H-phenothiazine.

名称と識別子

優先名称
Perphenazine
IUPAC
2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
現地名
ペルフェナジン
英語名
PERPHENAZINE
分子式
C21H26ClN3OS
分子量
403.97

名称と別名

perphenazine58-39-9TrilafonPerphenazinPerfenazineEtaperazineChlorpiprazineEtaperazinEthaperazinePerphenanFentazinPerfenazina
名称をさらに表示
ペルフェナジン2-クロロ-10-[3-[4-(2-ヒドロキシエチル)ピペラジン-1-イル]プロピル]フェノチアジン4-[3-(2-クロロフェノチアジン-10-イル)プロピル]-1-ピペラジンエタノールペルフェナジン (JP17)デセンタン2-クロロ-10-[3-[4-(2-ヒドロキシエチル)ピペラジン-1-イル]プロピル]-10H-フェノチアジンクロルピプラジントリラホン2-[4-[3-(2-クロロ-10H-フェノチアジン-10-イル)プロピル]-1-ピペラジニル]エタノール4-[3-(2-クロロ-10H-フェノチアジン-10-イル)プロピル]ピペラジン-1-エタノール2-{4-[3-(2-クロロ-10H-フェノチアジン-10-イル)プロピル]ピペラジン-1-イル}エタン-1-オールペルフェナンピーゼットシートリラフォン2-クロロ-10-[3-[4-(2-ヒドロキシエチル)-1-ピペラジニル]プロピル]-10H-フェノチアジンエタペラジンクロルピプロジンフェンタジン10-[3-[4-(2-ヒドロキシエチル)ピペラジン-1-イル]プロピル]-2-クロロ-10H-フェノチアジントリファロンPZCF-monsch3940Sch 3940
DecentanChlorperphenazineThilatazinTrifaronTriphenotEmesinalTrilifanPerphenazinum

物性

構造計算による物性補完中

XLogP
4.2
極性表面積
55.3 Ų
水素結合供与体数
1
水素結合受容体数
5
回転可能結合数
6
重原子数
27
形式電荷
0
複雑度
463

実験および物理化学的性質

Drugs · 3 件

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

pHpH = 4.2 - 5.6
LogP · 3 件

log Kow = 4.20

3.9

4.25

OdorAlmost odorless
TasteBitter taste
Color/Form · 2 件

Crystals

White to creamy-white powder

Solubility · 3 件

Solubility (mg/mL): ethanol 153; acetone 82; practically insoluble in sesame oil

In water, 2.83X10-2 g/L (28.3 mg/L) at 24 °C

2.37e-02 g/L

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antipsychotic Agents; Phenothiazines

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling Point · 2 件

278-281 °C at 1.00E+00 mm Hg

BP: 214-218 °C at 0.15 mm Hg; 278-281 at 1 mm Hg

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H302 (96.3%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P354+P338, P316, P317, P318, P320, P321, P330, P333+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Other Safety InformationIMAP assessments - 1-Piperazineethanol, 4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-: Environment tier I assessment
FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including perfenazine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Hazard Classes and CategoriesAcute Tox. 4 (96.3%)
Skin, Eye, and Respiratory Irritations · 1 件

May cause irritation /to the eyes, skin, and mucous membranes/. Avoid inhalation. Remove to fresh air. Avoid contact. Flush /eyes/ with copious quantities of tepid water. Avoid /skin/ contact. Flush with copious quantities of soap and water.

Hazardous Reactivities and IncompatibilitiesPerphenazine should not be mixed with tea as precipatation of insoluble tannates may occur.

安全と保護具

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Perphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.

Mechanism of Action · 6 件

Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.

The principal pharmacologic effects of "perphenazine" are similar to those of chlorpromazine. "Perphenazine" has moderate anticholinergic effects, weak to moderate sedative effects, and strong extrapyramidal effects. "Perphenazine" has strong antiemetic activity.

The development of phenothiazine derivatives as psychopharmacologic agents resulted from the observation that certain phenothiazine antihistaminic compounds produced sedation. In an attempt to enhance the sedative effects of these drugs, promethazine and chlorpromazine were synthesized. Chlorpromazine is the pharmacologic prototype of the phenothiazines. The pharmacology of phenothiazines is complex, and because of their actions on the central and autonomic nervous systems, the drugs affect many different sites in the body. Although the actions of the various phenothiazines are generally similar, these drugs differ both quantitatively and qualitatively in the extent to which they produce specific pharmacologic effects. /Phenothiazine General Statement/

In the CNS, phenothiazines act principally at the subcortical levels of the reticular formation, limbic system, and hypothalamus. Phenothiazines generally do not produce substantial cortical depression; however, there is minimal information on the specific effects of phenothiazines at the cortical level. Phenothiazines also act in the basal ganglia, exhibiting extrapyramidal effects. The precise mechanism(s) of action, including antipsychotic action, of phenothiazines has not been determined, but may be principally related to antidopaminergic effects of the drugs. There is evidence to indicate that phenothiazines antagonize dopamine-mediated neurotransmission at the synapses. There is also some evidence that phenothiazines may block postsynaptic dopamine receptor sites. However, it has not been determined whether the antipsychotic effect of the drugs is causally related to their antidopaminergic effects. Phenothiazines also have peripheral and/or central antagonistic activity against alpha-adrenergic, serotonergic, histaminic (H1-receptors), and muscarinic receptors. Phenothiazines also have some adrenergic activity, since they block the reuptake of monoamines at the presynaptic neuronal membrane, which tends to enhance neurotransmission. The effects of phenothiazines on the autonomic nervous system are complex and unpredictable because the drugs exhibit varying degrees of alpha-adrenergic blocking, muscarinic blocking, and adrenergic activity. The antipsychotic activity of phenothiazines may be related to any or all of these effects, but it has been suggested that the drugs' effects on dopamine are probably most important. It has also been suggested that effects of phenothiazines on other amines (eg, gamma-aminobutyric acid [GABA]) or peptides (eg, substance P, endorphins) may contribute to their antipsychotic effect. Further study is needed to determine the role of central neuronal receptor antagonism and of effects on biochemical mediators in the antipsychotic action of the phenothiazines and other antipsychotic agents. /Phenothiazine General Statement/

関連反応

2 件
反応記録を作成
HRID 192982 の反応式
HRID 192982反応物として
HRID 2417972 の反応式
HRID 2417972反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
58-39-9
PubChem CID
4748
DTXSID
DTXSID1023441
ChEMBL
CHEMBL567
ChEBI
CHEBI:8028
UNII
FTA7XXY4EZ
EC Number
200-381-5
Nikkaji
J1.387K
DecompositionWhen heated to decomposition it emits very toxic fumes of /sulfur and nitrogen oxides/ and /hydrogen chloride/.
Melting Point · 3 件

97 °C

Crystals from alcohol, MP: 225-226 °C /Dihydrochloride/

97 °C

Physical DescriptionSolid

物理化学的性質

融点
95 · 95-98C
沸点
0.15 · bp0.15 214-218°; bp1 278-281°
比重(密度)
1.253 · 1.253
屈折率
1.61 · 1.6100 (estimate)
貯蔵温度
2 · 2-8°C
溶解性
水にほとんど溶けず、ジクロロメタンに易溶、エタノールに可溶(96%)。希塩酸溶液に可溶。
酸解離定数(Pka)
7.8 · pKa 7.8(H2O,t =24±1) (Uncertain)
外見
Solid
色
白い
水溶解度
28.28 mg/L · 28.28mg/L(24℃)
Merck
14 · 14,7183
安定性
-20 °Cで最大3か月保存できます。 · DMSO溶液またはエタノール溶液で-20°Cで最大3か月保存できます。
主な用途
臨床検査
InChI
InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
InChIKey
RGCVKNLCSQQDEP-UHFFFAOYSA-N
SMILES
N1(CCO)CCN(CCCN2C3=CC(Cl)=CC=C3SC3=C2C=CC=C3)CC1
CAS データベース
58 · 58-39-9(CAS DataBase Reference)

化学的性質

化学的特性Off-White to Pale Yellow Solid

Fire Fighting Procedures · 2 件

Water spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and materials.

As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.

Storage Conditions · 2 件

Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

Commercially available preparations of perphenazine should be stored in tight, light-resistant containers. Perphenazine tablets and oral concentrate solution should be stored at 2-25 and 2-30 °C, respectively; freezing of the oral concentrate solution should be avoided.

Cleanup Methods · 1 件

Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using a high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site.

Disposal Methods · 2 件

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

Preventive Measures · 5 件

SRP: The scientific literature for the use of contact lenses by industrial workers is inconsistent. The benefits or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential buildup of static electricity.

As a general rule, when handling USP Reference Standards avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Wash thoroughly after handling.

Use safety glasses or goggles and protect exposed skin.

Personal Protective Equipment (PPE) · 2 件

Engineering controls such as exhaust ventilation are recommended.

Use a NIOSH approved respirator, if it is determined to be necessary by an industrial hygiene survey involving air monitoring. In the event that a respirator is not required, an approved dust mask should be used.

毒性情報

Treatment · 1 件

Treatment is symptomatic and supportive. Induction of emesis is not recommended because of the possibility of a seizure, CNS depression, or dystonic reaction of the head or neck and subsequent aspiration. Gastric lavage (after intubation, if the patient is unconscious) and administration of activated charcoal together with a laxative should be considered. There is no specific antidote. Standard measures (oxygen, intravenous fluids, corticosteroids) should be used to manage circulatory shock or metabolic acidosis. An open airway and adequate fluid intake should be maintained. Body temperature should be regulated. Hypothermia is expected, but severe hyperthermia may occur and must be treated vigorously. An electrocardiogram should be taken and close monitoring of cardiac function instituted if there is any sign of abnormality. Close monitoring of cardiac function is advisable for not less than five days. Vasopressors such as norepinephrine may be used to treat hypotension, but epinephrine should NOT be used. (L1712)

Interactions · 5 件

Since phenothiazines and central nervous system depressants (opiates, analgesics, antihistamines, barbiturates) can potentiate each other, less than the usual dosage of the added drug is recommended and caution is advised when they are administered concomitantly.

Perphenazine ... increased t1/2 of amphetamine in brain. However, despite elevated amphetamine levels, amphetamine-induced pharmacological effects were inhibited.

It appears that whether given im or orally, antiparkinsonism drugs biperidine & orphenadine have no significant effect on previously attained levels of perphenazine and its metabolites in psychotic pt.

QT interval-prolonging medications, including cisapride, erythromycin, and quinidine /may produce/ additive QT interval prolongation increasing the risk of developing cardiac arrhythmias when /concurrently administered with phenothiazines/. /Phenothiazines/

For more Interactions (Complete) data for Perphenazine (31 total), please visit the HSDB record page.

Hepatotoxicity · 1 件

Transient liver test abnormalities occur in a proportion of patients on long term therapy with perphenazine and other phenothiazines, but the elevations are usually mild, asymptomatic and reverse even with continuation of medication. Chlorpromazine, the prototype phenothiazine, is a well known cause clinically apparent acute liver injury which occurs in approximately 1% of treated patients. It is unclear whether perphenazine causes a similar syndrome, but if so, it is rare and far less common than with chlorpromazine. Case series of drug induced liver injury have occasionally listed perphenazine as a cause, but the clinical characteristics of the injury have not been described. Typical phenothiazine induced liver injury usually presents within 1 to 4 weeks of starting therapy, with a cholestatic or mixed pattern of serum enzyme elevations. Immunoallergic manifestations (fever and eosinophilia) are common but usually not prominent, and autoantibodies are rare. Phenothiazine induced jaundice can be severe and prolonged and result in vanishing bile duct syndrome, but is rarely fatal.

Exposure RoutesAbsolute bioavailability is 40% following oral administration.
Milk ConcentrationsPhenothiazines are distributed into milk. The manufacturers warn that nursing should not be undertaken by women receiving phenothiazines. /Phenothiazine General Statement/
Toxicity Summary · 1 件

Binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.

Signs and SymptomsSymptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours.
Human Toxicity Excerpts · 5 件

/SIGNS AND SYMPTOMS/ The toxic effects of perphenazine are typically mild to moderate with death occurring in cases involving a large overdose. Overdosage of perphenazine primarily involves the extrapyramidal mechanism and produces the same adverse reactions /of phenothiazines/, but to a more marked degree. It is usually evidenced by stupor or coma; children may have convulsive seizures. Signs of arousal may not occur for 48 hours. The primary effects of medical concern are cardiac in origin including tachycardia, prolongation of the QRS or QTc intervals, atrioventricular block, torsade de pointes, ventricular dysrhythmia, hypotension or cardiac arrest, which indicate serious poisoning. Deaths by deliberate or accidental overdosage have occurred with this class of drugs.

/SIGNS AND SYMPTOMS/ In general, overdosage of phenothiazines may be expected to produce effects that are extensions of common adverse reactions; severe extrapyramidal reactions, hypotension, and sedation have been the principal effects reported. CNS depression progressing to coma with areflexia or CNS stimulation with convulsions followed by respiratory depression may occur; patients with early or mild intoxication may experience drowsiness, restlessness, disorientation, confusion, and excitement. Other reported effects associated with acute phenothiazine overdosage have included shock (eg, ECG changes and cardiac arrhythmias), increased QT and PR intervals, non-specific ST and T wave changes, bradycardia, sinus tachycardia, bilateral bundle branch block, atrioventricular block, ventricular tachycardia, ventricular fibrillation, torsades de pointes, myocardial depression, agitation, dry skin, nasal congestion, urinary retention, oliguria, uremia, blurred vision, hypothermia, hyperthermia, mydriasis, miosis, tremor, muscle twitching, spasm or rigidity, seizures, muscular hypotonia, constipation, ileus, dry mouth, vomiting, difficulty in swallowing or breathing, cyanosis, and respiratory and/or vasomotor collapse, and pulmonary edema, possibly with sudden apnea. /Phenothiazine general Statement/

/SIGNS AND SYMPTOMS/ Sudden and unexpected deaths have occurred in patients receiving phenothiazines, especially during long-term administration of the drugs. In some patients, sudden death appeared to result from asphyxia (secondary to failure of the cough reflex) or cardiac arrest. /Phenothiazine General Statement/

/CASE REPORTS/ A small number of cases have been presented in the world literature in which treatment with phenothiazines resulted in clinical and laboratory manifestations of systemic lupus erythematosus (SLE). The clinical picture of such patients tends to be "symptom poor". A 26-year-old patient is presented who had a 7-year history of treatment for a schizophrenic illness and developed clinical as well as laboratory evidence for SLE. The differential diagnosis included: a) phenothiazine-induced SLE; b) SLE presenting with psychosis as a symptom; and c) SLE and sychosis occurring independently. The patient had a complete medical and neuropsychiatric work-up and was followed for 12 months. This challenging diagnostic problem is discussed. Phenothiazine-induced SLE was the most likely diagnosis. Although the possibility of two diseases occurring independently in the same person did not explain the clinical and laboratory data, it is difficult to rule out this possibility completely. SLE presenting with psychosis as a symptom could be ruled out by the work-up and history.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Perphenazine

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 4 件

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Perphenazine (PER), a potent phenothiazine, was administered to rats in a dose of 5 mg/kg, IP, daily for 19 days (experiment I) and 26 days (experiment II). In the first experiment, weights 3 days after treatment ended were PER 308 +/- 16 gm and saline controls 329 +/- 25 gm (P less than 0.01). Lengths were also smaller (221 +/- 2.2 mm vs 230 +/- 1.0 mm, P less than 0.05), and the slope of the growth curves for weight and length differed significantly as well. In a second experiment, the liquid diet pair-feeding technique was employed and demonstrated that the growth retardation due to PER could not be accounted for by a decrease in food intake. Pair-fed saline-treated rats who ate 2% less than PER-treated rats had a weight of 264 +/- 6 gm at the end of treatment compared to 236 +/- 9 gm for PER treated (P less than 0.01). It is concluded that PER treatment produces growth retardation and that this is not due simply to decreased food intake. The inhibition of growth hormone secretion produced by PER may be the mechanism of its growth-retarding effect.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Perphenazine in doses of 10--50 mg kg-1 day-1 given at the early stages of pregnancy delayed nidation up to day 8 of pregnancy. Once nidation had occurred the length of the rest of the gestation period was normal. Doses of up to 20 mg perphenazine kg-1 day-1, injected on days 1--7, prolonged gestation but the mothers and young were apparently normal; lower doses were effective only when treatment commenced soon after copulation. The delay in implantation of the ovum caused by perphenazine was corrected and and implantation was brought about immediately, by injection of 0.1 microgram oestradiol together with perphenazine. It is suggested that perphenazine delays and prevents implantation in rats by counteracting oestrogen release from the ovaries.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ The teratogenic effect of perphenazine was studied in closed-bred Wistar rats. Rats were given the substance orally continuously on days 7 to 14 of pregnancy, or as a single dose on one of days 9-15. The doses were considerably higher than the specific neuroleptic doses of perphenazine (20-150 mg/kg). The fetal mortality and malformation rates were significantly higher in the perphenazine-treated groups than in the controls. The results were compared with the earlier results of methophenazine treatment. Perphenazine was found to be more toxic for rat embryos than methophenazine.

/OTHER TOXICITY INFORMATION/ In rats with mammary tumors sc administration of 5 mg/kg of perphenazine daily for 14 days after ovariectomy, produced increases in prolactin concentrations and either regression or growth of certain tumors.

Populations at Special Risk · 2 件

The pharmacokinetics of perphenazine covary with the hydroxylation of debrisoquine which is mediated by cytochrome P450 2D6 (CYP 2D6) and thus is subject to genetic polymorphism - ie, 7% to 10% of Caucasians and a low percentage of Asians have little or no activity and are called "poor metabolizers." Poor metabolizers of CYP 2D6 will metabolize perphenazine more slowly and will experience higher concentrations compared with normal or "extensive" metabolizers.

Geriatric patients appear to be particularly sensitive to adverse nervous system (eg, tardive dyskinesia, parkinsonian signs and symptoms, akathisia, sedation), anticholinergic, and cardiovascular (eg, orthostatic hypotension) effects of antipsychotic agents. Because the risk of falling and associated hip fracture in geriatric patients may be increased with use of antipsychotic agents, phenothiazine therapy should be initiated at reduced dosages and such patients observed closely. /Phenothiazine General Statement/

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, including perfenazine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
3
rtecs
TL7175000
ridadr
UN 2811 6.1 / PGII
毒性
LD50 oral in rat: 318mg/kg
hs_code
29349990
risk_code
22-43
化審法
(9)-456
hazard_code
Xn
safety_code
28-36/37/39-45
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
ストレージクラス
3 - Flammable liquids
有毒物質データの
58-39-9(Hazardous Substances Data)

Although the exact mechanism(s) of action has not been conclusively determined, phenothiazines have an antiemetic effect. The antiemetic activity may be mediated via a direct effect of the drugs on the medullary chemoreceptor trigger zone (CTZ), apparently by blocking dopamine receptors in the CTZ. Phenothiazines inhibit the central and peripheral effects of apomorphine and ergot alkaloids. Phenothiazines generally do not inhibit emesis caused by the action of drugs at the nodose ganglion or by local action on the GI tract. /Phenothiazine General Statement/

For more Mechanism of Action (Complete) data for Perphenazine (14 total), please visit the HSDB record page.

Biological Half-Life · 4 件

8-12 hours, but ranges up to 20 hours.

The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours.

...The average terminal half-life of PPZ was approximately 9.5 hours. ...

Peak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours with a terminal phase half-life ranging between 9.9 to 18.8 hours.

Metabolism/Metabolites · 6 件

Hepatic.

Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.

Most metabolites of phenothiazines are pharmacologically inactive; however, certain metabolites (eg, 7-hydroxychlorpromazine, mesoridazine) show moderate pharmacologic activity and may contribute to the action of the drugs. There is limited evidence to indicate that some phenothiazines (eg, chlorpromazine) may induce their own metabolism. /Phenothiazine General Statement/

The pharmacokinetics of a single oral dose of 6 mg perphenazine was studied in a group of six slow and six rapid hydroxylators of debrisoquin. Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001). The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001). The data suggest that the disposition of the antipsychotic drug perphenazine covaries with polymorphic debrisoquin hydroxylation.

After chronic administration of piperazine-substituted phenothiazine drugs ... to rats, tissues contained drug metabolites, in which piperazine ring fission by multiple oxidative n-dealkylation had occurred to give substituted ethylenediamine. Thus, n-[gamma-(2-chlorophenothiazinyl-10)-propyl]ethylenediamine ... from ... perphenazine ...

Perphenazine has known human metabolites that include N-Dealkylated perphenazine and Perphenazine sulfoxide.

FDA Pharmacological Classification · 6 件

FTA7XXY4EZ

PERPHENAZINE

Established Pharmacologic Class [EPC] - Phenothiazine

Chemical Structure [CS] - Phenothiazines

Perphenazine is a Phenothiazine.

PERPHENAZINE

MeSH Pharmacological Classification · 2 件

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Absorption, Distribution and Excretion · 6 件

Absolute bioavailability is 40% following oral administration.

Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.

Phenothiazines are generally well absorbed from the GI tract and from parenteral sites; however, absorption may be erratic, particularly following oral administration. Considerable interindividual variations in peak plasma concentrations have been reported. The variations in peak plasma concentrations may result from genetic differences in the rate of metabolism, biodegradation of the drug in the GI lumen, and/or metabolism of the drug during absorption (in the GI mucosa) and first pass through the liver. /Phenothiazine General Statement/

Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. ... In a study in which normal volunteers (n=12) received perphenazine 4 mg q8h for 5 days, steady-state concentrations of perphenazine were reached within 72 hours.

Phenothiazines and their metabolites are distributed into most body tissues and fluids, with high concentrations being distributed into the brain, lungs, liver, kidneys, and spleen. /Phenothiazine General Statement/

Phenothiazines are highly bound to plasma proteins. /Phenothiazine General Statement/

Cellular LocationsMembrane

用途と製造

Uses · 6 件

THERAPEUTIC CATEGORY: Antipsychotic

THERAPEUTIC CATEGORY (VETERINARY): Tranquilizer, pre-anesthetic agent

MEDICATION (VET)

MEDICATION

Use (kg; approx.) in Germany (2009): >25

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Methods of ManufacturingA toluene solution of 2-chloro-10-(3-chloropropyl)phenothiazine and 1-piperpazineethanol is refluxed with sodamide and the resulting perphenazine purified by means of vacuum distillation.
Formulations/PreparationsPerphenazine preparations: (AHFS, 2010):
Use ClassificationPharmaceuticals
応用分野 · 3 件

解説ペルフェナジンは,フェノチアジン系の向精神薬。静穏作用が強く,鎮静,強化麻酔,制吐作用なども示す。同系のクロルプロマジンに比して,傾眠状態を起こすことが少なく,鎮静作用も比較的弱いが,制吐作用は非常に強い。精神病治療にも有効で,陳旧な統合失調症患者に対して,疎通性,接触性の回復および,意欲,自発性の促進作用を強く現す。副作用は嗜眠,軽度の血圧下降,パーキンソン様症状などがあるが,クロルプロマジンに比して弱い。ブリタニカ国際大百科事典 小項目事典 ブリタニカ

使用D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro. Antipsychotic.

一般的な説明Perphenazine, 4-[3-(2-chlorophenothiazine-10-yl)propyl]piperazineethanol; 2-chloro-10-[3-[4-(2-hydroxyethyl)piperazinyl]propyl]phenothiazine(Trilafon), is an effective antipsychotic and antiemetic.

上流・下流製品情報

上流原料

2-クロロフェノチアジンプロクロルペラジン1-ブロモ-3-クロロプロパン2-ブロモエタノール

補足説明

定義ChEBI: A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.

For more Human Toxicity Excerpts (Complete) data for Perphenazine (13 total), please visit the HSDB record page.